Palliative Sedation

Palliative Sedation - Last Resort Comfort

• Definition: Monitored use of medications to induce a state of ↓ or absent awareness (unconsciousness).
• Purpose: To relieve intractable and refractory symptoms in imminently dying patients.
  • Intent is to relieve suffering, not to hasten death.
• Indications: Severe refractory symptoms like dyspnea, pain, agitated delirium, existential distress.
• Key Drugs:
  • Midazolam (most common, short-acting benzodiazepine).
  • Levomepromazine, phenobarbital, propofol (specialist use).
• Process: Requires informed consent (patient/proxy), clear documentation, ongoing assessment, multidisciplinary team.

⭐ Palliative sedation is considered when the patient is in the last days or weeks of life and all other palliative treatments have failed to provide adequate symptom relief.

Palliative Sedation - When & Why Carefully

• Primary Goal: Alleviate intolerable, refractory suffering in patients at the very end of life by reducing consciousness.
• Key Indications:
  • Severe, uncontrolled physical symptoms (e.g., pain, dyspnea, agitated delirium).
  • Symptoms persist despite optimal palliative efforts.
• Crucial Prerequisites & Process:
  • Explicit consent (patient/surrogate) & multidisciplinary team (MDT) consensus.
  • Prognosis typically very short (days to few weeks).
  • Use lowest effective dose of sedative (e.g., Midazolam).
  • Continuous monitoring and holistic care.
  • ⚠️ Not euthanasia; intent is symptom relief.

⭐ Intent is paramount: Palliative sedation aims to relieve suffering, not to hasten death, distinguishing it ethically and legally from euthanasia.

Palliative Sedation - Checking All Boxes

• Goal: Relieve refractory symptoms in terminal illness, not hasten death.
• Indications: Severe, intractable distress (dyspnea, pain, delirium) unresponsive to standard treatments.
• Prerequisites:
  • Comprehensive assessment: diagnosis, prognosis (< 2 weeks), symptom burden.
  • Exploration of all other palliative options.
  • Multidisciplinary team (MDT) consensus.
  • Informed consent: patient (if competent) or legally authorized representative.
    • Discuss goals, benefits, risks (loss of consciousness, potential for hastened death as side effect).
  • Documentation: detailed rationale, consent process, plan.

⭐ Palliative sedation is ethically and legally distinct from euthanasia; the primary intention is symptom relief, not causing death.

• Monitoring: Regular assessment of sedation depth and symptom control. Titrate medication to achieve comfort. Re-evaluate if goals not met.

Palliative Sedation - Gentle Sleep Agents

Indicated for refractory symptoms in terminal illness. Aim: achieve comfort by reducing consciousness.

• Midazolam (Benzodiazepine): First-line agent.
  • Route: SC, IV.
  • Bolus: 0.5-5 mg.
  • Infusion: 1-20 mg/hr (or higher based on response); titrate q30-60min.
  • Rapid onset, short half-life, reversible.
• Levomepromazine (Antipsychotic): Second-line or for agitated delirium.
  • Route: SC, PO.
  • Dose: 12.5-25 mg SC q4-8h; or continuous SC infusion 25-200 mg/24h.
• Phenobarbital (Barbiturate): For refractory sedation.
  • Route: SC, IV.
  • Loading dose: 200 mg SC/IV.
  • Continuous infusion: 600-1200 mg/24h SC.
• Monitoring:
  • Sedation depth (e.g., RASS target -4 to -5).
  • Respiratory status, vital signs, comfort.

⭐ Midazolam is the most commonly used drug for palliative sedation due to its rapid onset of action, short duration, ease of titration, and availability of an antagonist (flumazenil).

High‑Yield Points - ⚡ Biggest Takeaways

• Palliative sedation is for refractory symptoms in imminently dying patients.
• Goal: Relieve intolerable suffering, not to hasten death.
• Doctrine of Double Effect is the guiding ethical principle.
• Midazolam is the first-line agent; others include phenobarbital, propofol.
• Requires informed consent and multidisciplinary team involvement.
• Crucial distinction from euthanasia based on intent and outcome.
• Monitor for symptom relief and level of consciousness regularly.